PAR DRUGS AND CHEMICALS
|
PAR DRUGS AND CHEMICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.65 | 10.86 | 11.79 | 9.21 | 7.49 |
| CEPS(Rs) | 13.66 | 13.82 | 14.58 | 11.84 | 10.15 |
| DPS(Rs) | - | - | - | - | 1.25 |
| Book NAV/Share(Rs) | 91.01 | 80.44 | 69.59 | 57.90 | 48.66 |
| Tax Rate(%) | 24.23 | 25.47 | 25.70 | 24.84 | 27.47 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 14.73 | 17.20 | 21.27 | 16.81 | 19.16 |
| EBIT Margin(%) | 14.99 | 15.88 | 18.29 | 14.04 | 15.51 |
| Pre Tax Margin(%) | 14.88 | 15.81 | 18.20 | 13.92 | 14.97 |
| PAT Margin (%) | 11.27 | 11.78 | 13.52 | 10.46 | 10.86 |
| Cash Profit Margin (%) | 14.46 | 15.00 | 16.72 | 13.45 | 14.73 |
| Performance Ratios | |||||
| ROA(%) | 10.55 | 12.09 | 15.23 | 13.53 | 11.88 |
| ROE(%) | 12.43 | 14.47 | 18.49 | 17.29 | 16.44 |
| ROCE(%) | 16.52 | 19.51 | 25.02 | 23.20 | 21.85 |
| Asset Turnover(x) | 0.94 | 1.03 | 1.13 | 1.29 | 1.09 |
| Sales/Fixed Asset(x) | 1.54 | 1.52 | 1.52 | 1.70 | 1.51 |
| Working Capital/Sales(x) | 2.30 | 2.96 | 2.27 | 3.06 | 2.96 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.65 | 0.66 | 0.66 | 0.59 | 0.66 |
| Receivable days | 45.11 | 48.97 | 52.21 | 59.70 | 66.50 |
| Inventory Days | 18.02 | 16.55 | 16.26 | 17.00 | 16.58 |
| Payable days | 80.33 | 77.76 | 72.63 | 84.87 | 110.04 |
| Valuation Parameters | |||||
| PER(x) | 7.38 | 7.82 | 18.28 | 15.20 | 21.34 |
| PCE(x) | 5.75 | 6.15 | 14.78 | 11.83 | 15.73 |
| Price/Book(x) | 0.86 | 1.06 | 3.10 | 2.42 | 3.28 |
| Yield(%) | - | - | - | - | 0.78 |
| EV/Net Sales(x) | 0.53 | 0.76 | 2.39 | 1.57 | 2.40 |
| EV/Core EBITDA(x) | 2.60 | 3.55 | 9.91 | 8.13 | 10.97 |
| EV/EBIT(x) | 3.15 | 4.27 | 11.64 | 9.86 | 13.71 |
| EV/CE(x) | 0.49 | 0.78 | 2.67 | 2.11 | 2.29 |
| M Cap / Sales | 0.93 | 1.03 | 2.77 | 1.80 | 2.62 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.66 | 5.58 | -0.11 | 27.54 | 23.58 |
| Core EBITDA Growth(%) | -2.40 | -6.11 | 25.02 | 12.21 | 1.46 |
| EBIT Growth(%) | -3.20 | -8.25 | 29.00 | 15.62 | -14.39 |
| PAT Growth(%) | -1.87 | -7.88 | 27.94 | 23.02 | -20.65 |
| EPS Growth(%) | -1.87 | -7.88 | 27.94 | 23.02 | -60.33 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 4.68 | 3.31 | 4.79 | 3.53 | 2.93 |
| Quick Ratio(x) | 4.29 | 2.94 | 4.46 | 3.15 | 2.61 |
| Interest Cover(x) | 136.91 | 219.31 | 183.23 | 114.21 | 28.97 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of PAR DRUGS AND CHEMICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| PAR DRUGS AND CHEMICALS | ₹127.2 Cr | -5.6% | -25% | 2.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,204.0 Cr | -1% | -5.5% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹238,497.0 Cr | -2.6% | -3.9% | 38.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹170,481.0 Cr | -1.7% | -10.2% | 30.5% | Stock Analytics | |
| CIPLA | ₹108,012.0 Cr | 0.9% | -3.2% | -15.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,207.0 Cr | -0.6% | 1% | -0.1% | Stock Analytics | |
PAR DRUGS AND CHEMICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PAR DRUGS AND CHEMICALS | -5.6% |
-25% |
2.4% |
| SENSEX | -1.6% |
-2.3% |
-11.5% |
You may also like the below Video Courses
